bicalutamide apotex 50 mg tabletki powlekane
apotex europe b.v. - bicalutamidum - tabletki powlekane - 50 mg
bicalutamida pentafarma 50 mg tabletki powlekane
pentafarma-sociedade tecnico-medicinal, s.a. - bicalutamidum - tabletki powlekane - 50 mg
bicalutamida pentafarma 150 mg tabletki powlekane
pentafarma-sociedade tecnico-medicinal, s.a. - bicalutamidum - tabletki powlekane - 150 mg
bicalutamide accord 50 mg tabletki powlekane
accord healthcare polska sp. z o.o. - bicalutamidum - tabletki powlekane - 50 mg
bicalutamide kabi 50 mg tabletki powlekane
fresenius kabi polska sp. z o.o. - bicalutamidum - tabletki powlekane - 50 mg
casodex 50 mg tabletki powlekane
astrazeneca ab - bicalutamidum - tabletki powlekane - 50 mg
xtandi
astellas pharma europe b.v. - enzalutamid - nowotwory stercza - terapia endokrynologiczna - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
firmagon
ferring pharmaceuticals a/s - degareliks - nowotwory stercza - terapia endokrynologiczna - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
zoladex 3,6 mg implant podskórny
astrazeneca ab - goserelini acetas - implant podskórny - 3,6 mg
zoladex la 10,8 mg implant podskórny
astrazeneca ab - goserelini acetas - implant podskórny - 10,8 mg